|
CUPID (64Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer. |
| |
|
|
Stock and Other Ownership Interests - Telix Pharmaceuticals |
| |
|
|
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
Employment - Telix Pharmaceuticals |
Stock and Other Ownership Interests - Telix Pharmaceuticals |
| |
|
Employment - Telix Pharmaceuticals |
Leadership - Telix Pharmaceuticals |
Stock and Other Ownership Interests - Telix Pharmaceuticals |
| |
|
Employment - Telix Pharmaceuticals |
Leadership - Telix Pharmaceuticals |
Stock and Other Ownership Interests - Telix Pharmaceuticals |